eli lilly

Anyone else on the Jardiance contract? First day was today, what are your thoughts so far? Seems like a massive team. first time with Syneos, trying to get discussion started with some more experienced reps on what to expect.

Pharmaceutical company Eli Lilly (LLY) reported first-quarter 2020 revenue of $5.86 billion, up 15% year-over-year. Amid COVID-19 pandemic, the company saw increased customer buying patterns and prescription trends which resulted in a revenue increase of approx. $250 million for the quarter...

Eli Lilly surpassed earnings expectations for the third quarter of 2019 but revenues came in shy of estimates. Total revenue grew 3% year-over-year to $5.47 billion, but fell short of estimates of $5.5 billion. Revenues grew 4% excluding foreign currency impacts. Revenue growth was driven by an...

Clinical-stage biotech company Pfenex gets FDA's approval for PF708. Pfenex is conducting a comparative study between PF708 and Eli Lilly's Forteo and will submit the final study report to FDA later this month.

Eli Lilly lowered its earnings and revenue outlook for the full year 2019 due to the costs relating to the pending purchase of Loxo Oncology and the recent trial failure of cancer-treating Lartruvo. In the fourth quarter, revenue rose 5% driven by increased demand for newer medicines as well...

Axsome Therapeutics stock skyrockets on positive outcome from Alzheimer's disease trial https://news.alphastreet.com/axsome-therapeutics-nasdaq-axsm-stock-almost-doubles-on-positive-outcome-from-alzheimers-disease-trial-in-premarket/

Eli Lilly is aggressively broadening its cancer portfolio by purchasing Loxo Oncology for $8 billion! Loxo shareholders are having a field day with 85% premium on share price. Despite the expensive deal value, the purchase is highly appreciated due to Loxo's hitherto success in cancer treatment...

Eli Lilly to collaborate with AC Immune for the treatment of Alzheimer’s disease. Will it succeed and create a drug to cure Alzheimer's disease?

Wanted to start a conversation about this as it is the major initiative at Lilly. I have not seen any intelligent conversation about this. Just a lot of complaining. Who wants to start?

Celgene's second quarter results beat estimates and the company lifted 2018 outlook. Celgene will not be increasing the price of its products this year. https://news.alphastreet.com/celgene-q2-2018-earnings/

Investors have welcomed the move of Eli Lilly's decision to separate Elanco Animal Health business. Lilly stock hits a new 52-week high after the earnings announcement. David Ricks said, "As the responses to the Blueprint are considered, we are hopeful that progress will be made on implementing...

Trump has been speaking and tweeting about the higher drug prices for nearly two years and still he has not taken any steps in reducing the prices of the drugs. Pfizer and other pharma companies are taking advantage and increasing their drug prices often. When will this stop...

Adding to the list of the many failed studies on Alzheimer’s drugs in recent times – the most recent being vTv Therapeutics’ azeliragon – Eli Lilly Tuesday said it halted two advanced trials on lanabecestat, its experimental formulation for the treatment of the crippling brain disorder that...

In a deal aimed at expanding its oncology portfolio further, Eli Lilly will acquire cancer drug maker AurKa Pharma. The decision comes a few days after the pharma giant agreed to buy late-stage immune-oncology company ARMO Biosciences...

ARMO Biosciences loss in the fiscal year 2017 has increased compared to the fiscal year 2016. I don't know why Lilly is acquiring this loss making company. Will this acquisition really benefit Lilly? https://news.alphastreet.com/eli-lilly-acquires-armo-biosciences-strengthens-oncology-portfolio/

Eli Lilly reports an increase in pharma sales and decline in Animal Health. Lifts 2018 earnings outlook. When answering an analyst question, Enrique Conterno said, "We continue to see pressure on pricing across all of our diabetes products".

After raising the quarterly dividend recently, Lilly has provided outlook for 2018 and expects recently launched products to drive revenue. Dave Ricks says ""Looking to the future, the potential of our pipeline remains strong."

http://alph.st/bf3c0558 Lilly joins the migraine drug race with Novartis and Amgen, as FDA accepts to review Lilly's Galcanezumab. Already, Teva filed a lawsuit in October 2017, seeking to block Lilly's migraine drug to market in the U.S. The size of the migraine market is expected to more than...

Out of the 2300 employees, who accepted for the voluntary buyouts, majority employees are from Indiana. Exactly, two months back Lilly announced about 3500 job cuts

Check out the number of employees quarterwise from Sept 2016 to Sept 2017. The headcount had reduced drastically at the end of Sept 2017. http://alph.st/bcbcba96